CXCL13 and myeloid sarcoma: Apart from OCBs, alterations of the levels of interleukin (IL)-10 produced by naïve and/or regulatory B cells and the chemokine, CXCL13, which is a key regulator of B cell recruitment, have been reported in MS patients [9–11].